Polypid Ltd.

Polypid Ltd. company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications. Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer. Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden. We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems. NASDAQ: PYPD

Company Details

Employees
68
Address
Ha'sivim 18, Petah Tikva,israel
Phone
972 7 4719 5700
Email
in****@****pid.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
providers..
HQ
Petah Tikva
Looking for a particular Polypid Ltd. employee's phone or email?

Polypid Ltd. Questions

News

PolyPid to Present Its Positive Phase 3 SHIELD II Topline - GlobeNewswire

PolyPid to Present Its Positive Phase 3 SHIELD II Topline GlobeNewswire

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market - Yahoo Finance

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market Yahoo Finance

PolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical Congress - Quiver Quantitative

PolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical Congress Quiver Quantitative

Late-Stage Biopharma PolyPid Announces Double Conference Lineup: Lytham Partners and ROTH Healthcare - Stock Titan

Late-Stage Biopharma PolyPid Announces Double Conference Lineup: Lytham Partners and ROTH Healthcare Stock Titan

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Yahoo Finance

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results Yahoo Finance

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results GlobeNewswire

PolyPid Ltd. Completes Successful GMP Inspection by Israeli Ministry of Health, Preparing for NDA Submission of D-PLEX₁₀₀ - Quiver Quantitative

PolyPid Ltd. Completes Successful GMP Inspection by Israeli Ministry of Health, Preparing for NDA Submission of D-PLEX₁₀₀ Quiver Quantitative

Late-Stage Biopharma PolyPid Joins H.C. Wainwright Global Investment Conference for Key Presentation - Stock Titan

Late-Stage Biopharma PolyPid Joins H.C. Wainwright Global Investment Conference for Key Presentation Stock Titan

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference - Yahoo Finance

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference Yahoo Finance

PolyPid to Host Conference Call and Webcast to Discuss - GlobeNewswire

PolyPid to Host Conference Call and Webcast to Discuss GlobeNewswire

PolyPid Ltd. to Release Second Quarter 2025 Financial Results on August 13, 2025 - Quiver Quantitative

PolyPid Ltd. to Release Second Quarter 2025 Financial Results on August 13, 2025 Quiver Quantitative

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference - Yahoo Finance

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference Yahoo Finance

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints - GlobeNewswire

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints GlobeNewswire

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer - Yahoo Finance

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer Yahoo Finance

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀ - Yahoo Finance

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀ Yahoo Finance

PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire

PolyPid Announces Successful Completion of Enrollment in GlobeNewswire

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy - GlobeNewswire

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy GlobeNewswire

PolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA Approval - Nasdaq

PolyPid Secures $26.7 Million in Additional Funding to Extend Runway Ahead of D-PLEX₁₀₀ FDA Approval Nasdaq

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript - BioSpace

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript BioSpace

Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech - Yahoo Finance

Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech Yahoo Finance

Running Global Clinical Trials? PolyPid Shares Operational And Regulatory Insights - Clinical Leader

Running Global Clinical Trials? PolyPid Shares Operational And Regulatory Insights Clinical Leader

Earnings call transcript: PolyPid Q2 2025 sees wider losses, stock dips - Investing.com

Earnings call transcript: PolyPid Q2 2025 sees wider losses, stock dips Investing.com

PolyPid to Present at the Barclays Global Healthcare Conference - GlobeNewswire

PolyPid to Present at the Barclays Global Healthcare Conference GlobeNewswire

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City - Yahoo Finance

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City Yahoo Finance

Advanz bags EU rights to Polypid’s prolonged-release antibiotic - Fierce Pharma

Advanz bags EU rights to Polypid’s prolonged-release antibiotic Fierce Pharma

PolyPid Announces Positive Top-line Results from Phase 2 - GlobeNewswire

PolyPid Announces Positive Top-line Results from Phase 2 GlobeNewswire

PolyPid (PYPD) Stock Price, News & Analysis - MarketBeat

PolyPid (PYPD) Stock Price, News & Analysis MarketBeat

PYPD - Polypid Ltd. Latest Stock News & Market Updates - Stock Titan

PYPD - Polypid Ltd. Latest Stock News & Market Updates Stock Titan

PYPD Stock Price and Chart — NASDAQ:PYPD - TradingView

PYPD Stock Price and Chart — NASDAQ:PYPD TradingView

PolyPid reports positive phase 3 surgical infection drug trial - Globes - Israel Business News

PolyPid reports positive phase 3 surgical infection drug trial Globes - Israel Business News

PolyPid takes another IPO shot, seeking $86M as it preps for phase 3 - Fierce Biotech

PolyPid takes another IPO shot, seeking $86M as it preps for phase 3 Fierce Biotech

PolyPid plunges 73% after trial disappointment - Globes - Israel Business News

PolyPid plunges 73% after trial disappointment Globes - Israel Business News

Top 25 Biotech Companies which got Funded in Last 7 Days – 4409 Crores Rs - BioTecNika

Top 25 Biotech Companies which got Funded in Last 7 Days – 4409 Crores Rs BioTecNika

Top Polypid Ltd. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant